← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	ATHX 26 DELISTED Athersys, Inc. Common Stock ATHX	31	-1	-3%	$15.1M
27	27 Imunon IMNN $5.95M	29	-7	-19%	$7.86M
28	NSTG 28 DELISTED NanoString Technologies, Inc. NSTG	21	+18	+600%	$44.4M
29	29 Opus Genetics IRD $337M	20	0	0%	$2.34M
30	30 Arbutus Biopharma ABUS $850M	18	+7	+64%	$8.95M
31	31 Pluri PLUR $11.9M	17	-1	-6%	$1.29M
32	32 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	11	+5	+83%	$1.79M
33	ISEE 33 DELISTED IVERIC bio, Inc. Common Stock ISEE	9	+9	–	$32.6M
34	34 Eterna Therapeutics ERNA $2.53M	3	0	0%	$1.84M
35	35 DELISTED Scorpius Holdings, Inc. SCPX	1	+1	–	$8.71M
36	36 Abeona Therapeutics ABEO $266M	–	–	–	–
37	37 Adicet Bio ACET $48.1M	–	–	–	–
38	ACHL 38 DELISTED Achilles Therapeutics ACHL	–	–	–	–
39	39 DELISTED Arcellx ACLX	–	–	–	–
40	ADAP 40 DELISTED Adaptimmune Therapeutics ADAP	–	–	–	–
41	41 Adaptive Biotechnologies ADPT $4.08B	–	–	–	–
42	42 DELISTED Adverum Biotechnologies ADVM	–	–	–	–
43	AGTC 43 DELISTED Applied Genetic Technologies Corporation AGTC	–	–	–	–
44	AKUS 44 DELISTED Akouos Inc AKUS	–	–	–	–
45	45 Allogene Therapeutics ALLO $463M	–	–	–	–
46	46 ALPS Group Inc ALPS $56.4M	–	–	–	–
47	47 ARK Genomic Revolution ETF ARKG $2.09B	–	–	–	–
48	48 Artiva Biotherapeutics ARTV $296M	–	–	–	–
49	ATNX 49 DELISTED Athenex, Inc. Common Stock ATNX	–	–	–	–
50	50 Atara Biotherapeutics ATRA $96.9M	–	–	–	–